<DOC>
	<DOCNO>NCT01428479</DOCNO>
	<brief_summary>This study randomize , double-blind , ascend dose , placebo-controlled , incomplete crossover , single multiple dose study healthy Japanese male subject assess pharmacokinetics safety/tolerability single multiple intravenous administration GR121167 . Serial blood sample pool urine sample determination GR121167 concentration collect safety assessment perform treatment period . The pharmacokinetics dose proportionality GR121167 single intravenous administration GR121167 dose level 100 mg , 300 mg 600 mg assess . In addition , final treatment period ( 600 mg ) , twice daily intravenous administration 5 day also conduct pharmacokinetics accumulation assess .</brief_summary>
	<brief_title>Phase1 Study GR121167 , Single Multiple Dose Study Healthy Japanese Males</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<criteria>1 . Healthy define free clinically significant illness disease determine responsible experienced physician , base medical evaluation include medical history , physical examination , vital sign , laboratory test ECG . 2 . Japanese healthy male 20 55 year age inclusive , time signing informed consent . 3 . Body weight &gt; = 50.0 kg BMI within range 18.5 &lt; = &lt; 25.0 kg/m2 ( inclusive ) . 4 . A creatinine clearance &gt; = 80ml/min determined CockcroftGault equation : CLcr ( mL/min ) = ( 140 age ) * Wt / ( 72 * Scr ) . Where age year , weight ( wt ) kg , serum creatinine ( Scr ) unit mg/dl . [ Cockcroft , 1976 ] 5 . Nonsmoker exsmoker cease smoke least 6 month . 6 . AST , ALT , alkaline phosphatase total bilirubin = &lt; ULN screen . 7 . Capable give write informed consent , include compliance requirement restriction list consent form . 1 . A positive test syphilis , Hepatitis B surface antigen positive Hepatitis C antibody , HIV antigen /antibody , HTLV1 screen 2 . A positive prestudy drug screen screen . 3 . History regular alcohol consumption exceed , average , 14 drinks/week men ( 1 drink = 5 ounce ( 150 mL ) wine 350 mL beer 1.5 ounce ( 45 mL ) 80 proof distil spirit ) within 6 month screen . 4 . The subject participate clinical study postmarketing study investigational noninvestigational product previous 4 month precede first dose study medication study 5 . The subject plan concurrently participate another clinical study postmarketing study . 6 . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 14 day 5 halflives ( whichever longer ) prior first dose study medication . 7 . History sensitivity study medication , component thereof history drug allergy exclude pollen allergy without current symptom . 8 . Where participation study would result donation blood blood product excess 400 mL within 4 month 200 mL within 2 month . 9 . Unwillingness inability follow procedure outline protocol . 10 . Consumption red wine , grapefruit grapefruit juice 7 day prior first dose study medication . 11 . Single QTcB &gt; = 450 msec ; screen 12 . Subjects ECG result consider clinically significant investigator . 13 . Subjects personal history cardiac disease , symptomatic asymptomatic arrhythmia , syncopal episode additional risk factor torsades de pointes ( e.g. , heart failure , hypokalemia ) . 14 . Subjects family history sudden cardiac death . 15 . Subjects supine systolic blood pressure &lt; 90mmHg &gt; 140mmHg and/or supine diastolic blood pressure &lt; 55mmHg &gt; 90mmHg and/or systolic blood pressure drop supine stand &gt; 30mmHg . 16 . History renal failure renal dysfunction</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>